Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/JPA.0000000000000615 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patients with antiphospholipid antibodies preferentially seek health information from physicians: a cross-sectional online patient quantitative survey.
Rheumatol Int
January 2025
Division of Rheumatology, Department of Medicine, University of Calgary, Cumming School of Medicine, Calgary, AB, Canada.
Little is known about how patients with antiphospholipid syndrome (APS) or antiphospholipid antibodies (aPL) access and trust health information. This research aimed to: describe the sources of information most frequently accessed/trusted by patients with APS/aPL; identify if individuals with APS/aPL perceived their health had been negatively impacted by various sources and document obstacles to accessing health information. Patients meeting Revised Sapporo Criteria for APS or with ≥1 positive aPL on ≥2 occasions were recruited to an online survey regarding their health information use at diagnosis and within 6 months preceding survey completion.
View Article and Find Full Text PDFWilliam Budd: Revolutionizing Epidemiology and Public Health in the 19th Century.
Cureus
December 2024
General Medicine, Sikkim Manipal Institute of Medical Sciences and Central Referral Hospital, Gangtok, IND.
William Budd (1811-1880) was a pioneering British physician whose work on infectious diseases, particularly typhoid fever, significantly advanced the understanding of epidemiology and public health in the 19th century. This review examines Budd's life, medical career, and groundbreaking contributions to the study of infectious diseases, focusing on his influential research into the transmission of typhoid fever, advocacy for public health reforms, and lasting legacy in epidemiology. Through meticulous research and innovative thinking, Budd laid the groundwork for modern approaches to disease control and prevention, cementing his place as a key figure in medical history.
View Article and Find Full Text PDFProposed resources required for a comprehensive program for CCT CHD imaging.
J Cardiovasc Comput Tomogr
January 2025
Royal Brompton Hospital, London, England, USA; School of Biomedical Engineering and Imaging Sciences, King's College, London, USA. Electronic address:
Background: Cardiac Computed Tomography (CCT) is increasingly used for evaluation of congenital heart disease (CHD) in patients of all ages. Pediatric and adult congenital heart disease (ACHD) surgical programs require high quality CCT imaging as part of the multimodality imaging support expected of comprehensive care centers. Despite these expectations, there are no benchmarks or defined programmatic elements specific to the performance of CCT in patients with CHD.
View Article and Find Full Text PDFDefinition and diagnostic criteria of clinical obesity.
Lancet Diabetes Endocrinol
January 2025
Division of Diabetes & Nutritional Sciences, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London, UK; Catholic University of the Sacred Heart, Rome, Italy; University Polyclinic Foundation Agostino Gemelli IRCCS, Rome, Italy.
Cenobamate as add-on treatment for SCN8A developmental and epileptic encephalopathy.
Epilepsia
January 2025
Department of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Center, Dianalund, Denmark.
Objectives: Developmental and epileptic encephalopathies (DEEs) caused by pathogenic variants in SCN8A are associated with difficult-to-treat and early-onset seizures, developmental delay/intellectual disability, impaired quality of life, and increased risk of early mortality. High doses of sodium channel blockers are typically used to treat SCN8A-DEE caused by gain-of-function (GoF) variants. However, seizures are often drug resistant, and only a few patients achieve seizure freedom.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!